Apriem Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Apriem Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12	Closed	–	–	681
2017 Q1	$0	Hold	12	–	–	﹤0.01%	784
2016 Q4	$0	Hold	12	–	–	﹤0.01%	785
2016 Q3	$0	Hold	12	–	–	﹤0.01%	700
2016 Q2	$0	Hold	12	–	–	﹤0.01%	692
2016 Q1	$0	Hold	12	–	–	﹤0.01%	671
2015 Q4	$0	Hold	12	–	–	﹤0.01%	603
2015 Q3	$0	Hold	12	–	–	﹤0.01%	680
2015 Q2	$0	Hold	12	–	–	﹤0.01%	724
2015 Q1	$0	Hold	12	–	–	﹤0.01%	622
2014 Q4	$0	Buy	+12	New	+$48	﹤0.01%	596

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Apriem Advisors's AST Position: Q2 2017 in Review

Apriem Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2017, closing a stake of 12 shares.

Apriem Advisors first reported a position in AST in Q4 2014 and held it in 10 quarters. The position peaked at $0 in Q1 2017. 64 funds tracked by Wall St. Rank hold AST as of Q2 2017.

Apriem Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2017 after selling out during the quarter.
Apriem Advisors sold 12 Asterias Biotherapeutics Inc. Series A shares in Q2 2017.
Apriem Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 10 quarters.
Apriem Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q1 2017.
64 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2017.

Based on Apriem Advisors's 13F filing for Q2 2017, filed 4 Aug 2017.